stockrowPraxis Precision Medicines, Inc.
PRAX Healthcare Biotechnology
Praxis Precision Medicines, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $8.6 million, up 249.5% from fiscal 2023.
- Revenue
- +1,349.1%
- EPS
- +13.3%
- Free cash flow
- −43.5%
Quarter to June 2026, against a year earlier
Follow PRAX
Alert me
Praxis Precision Medicines, Inc. (PRAX) Free cash flow margin
Praxis Precision Medicines, Inc.'s free cash flow margin over the twelve months to 30 June 2026 was 0.00%, down 0.0 percentage points from fiscal 2025 (0.00%). Over the past ten years it has ranged from −4,543.8% (fiscal 2023) to 0.00% (fiscal 2025) — the current reading is the highest in ten years. That is in line with the Biotechnology industry median of 0.00% and in line with the Healthcare sector median of 0.00%.
Free cash flow margin, annual
Embed this chart
Annual newest first
| Period | Free cash flow margin | Change (points) |
|---|---|---|
| FY2025 | 0.00% | 1,540.48 |
| FY2024 | −1,540.5% | 3,003.29 |
| FY2023 | −4,543.8% | (4,543.77) |
| FY2022 | 0.00% | 0.00 |
| FY2021 | 0.00% | 0.00 |
| FY2020 | 0.00% | 0.00 |
| FY2019 | 0.00% | 0.00 |
| FY2018 | 0.00% | — |
Against its own ten years
Free cash flow margin against peers
| Company | Free cash flow margin |
|---|---|
| KRYS Krystal Biotech, Inc. compare | 66.0% |
| CORT Corcept Therapeutics Incorporated compare | 20.2% |
| PRAX Praxis Precision Medicines, Inc. | 0.00% |
| ABVX Abivax SA Sponsored ADR compare | 0.00% |
| SYRE Spyre Therapeutics, Inc. compare | 0.00% |
| AXSM Axsome Therapeutics, Inc. compare | −9.55% |
| ARWR Arrowhead Pharmaceuticals, Inc. compare | −11.2% |
| RYTM Rhythm Pharmaceuticals, Inc. compare | −29.1% |
| CYTK Cytokinetics, Incorporated compare | −519.5% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Free cash flow margin is
Free Cash Flow Margin tells an investor how much of each sale turns into cash the company keeps after paying for investment in its assets.
(Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)) ÷ Revenue